文献速递泌尿男性生殖肿瘤

多西他赛与卡巴他赛早期互换的随机非比较II期试验及整合生物标志物分析:用于化疗初治的转移性去势抵抗性前列腺癌男性

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2017-06-20

TAXYNERGY试验将化疗初治的转移性去势抵抗性前列腺癌男性按2:1随机分配至多西他赛或卡巴他赛,第4周期前PSA下降未达≥30%者互换紫杉烷。确认的≥50% PSA缓解率为55.6%,超过历史对照TAX327的45.4%。紫杉烷诱导的%ARNL下降与第4周期≥50% PSA下降率较高相关(P=0.009)。

要点

  • 63例患者随机分配至多西他赛(n=41)或卡巴他赛(n=22),44.4%既往接受过强效雄激素受体靶向治疗。
  • 35例(55.6%)确认≥50% PSA缓解,超过TAX327历史对照的45.4%。
  • 互换紫杉烷的患者中46.7%随后达到≥50% PSA下降。

核心结论

  • 早期互换紫杉烷策略与TAX327相比改善了PSA缓解率。
  • 紫杉烷诱导的%ARNL变化可能作为紫杉烷治疗患者临床获益的早期生物标志物。

研究设计与样本

  • 随机、非比较、II期试验(TAXYNERGY,ClinicalTrials.gov标识符NCT01718353),入组化疗初治的转移性去势抵抗性前列腺癌男性。
  • 患者按2:1随机分配至多西他赛或卡巴他赛,第4周期前未达到≥30% PSA下降者互换紫杉烷。
  • 主要临床终点为确认的≥50% PSA下降率对比历史对照(TAX327),主要生物标志物终点为分析治疗后循环肿瘤细胞(CTC)以确认临床缓解与紫杉烷药物-靶点结合相关。

主要发现

  • 63例患者随机分配至多西他赛(n=41)或卡巴他赛(n=22),44.4%既往接受过强效雄激素受体靶向治疗。
  • 总体35例(55.6%)确认≥50% PSA缓解,超过历史对照TAX327的45.4%。
  • 61例接受治疗的患者中,33例(54.1%)第4周期时≥30% PSA下降且未互换紫杉烷,15例(24.6%)第4周期时未达到≥30% PSA下降而互换紫杉烷,13例(21.3%)在第4周期前或第4周期时终止治疗。
  • 互换紫杉烷的患者中,46.7%随后达到≥50% PSA下降。
  • 26例可评估CTC的患者中,紫杉烷诱导的%ARNL下降(第1周期第1天 vs 第1周期第8天)与第4周期≥50% PSA下降率较高相关(P=0.009)。

关键数值与推荐

  • 确认的≥50% PSA缓解率:总体55.6%(35/63) vs TAX327历史对照45.4%。
  • 第4周期时≥30% PSA下降且未互换紫杉烷:54.1%(33/61)。
  • 第4周期时未达到≥30% PSA下降而互换紫杉烷:24.6%(15/61)。
  • 互换紫杉烷后达到≥50% PSA下降:46.7%。
  • 可评估CTC患者中%ARNL下降与第4周期≥50% PSA下降率较高相关:P=0.009(n=26)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. Patients and Methods Patients were randomly assigned 2:1 to docetaxel or cabazitaxel. Men who did not achieve ≥ 30% prostate-specific antigen (PSA) decline by cycle 4 (C4) switched taxane. The primary clinical endpoint was confirmed ≥ 50% PSA decline versus historical control (TAX327). The primary biomarker endpoint was analysis of post-treatment CTCs to confirm the hypothesis that clinical response was associated with taxane drug-target engagement, evidenced by decreased percent androgen receptor nuclear localization (%ARNL) and increased microtubule bundling. Results Sixty-three patients were randomly assigned to docetaxel (n = 41) or cabazitaxel (n = 22); 44.4% received prior potent androgen receptor-targeted therapy. Overall, 35 patients (55.6%) had confirmed ≥ 50% PSA responses, exceeding the historical control rate of 45.4% (TAX327). Of 61 treated patients, 33 (54.1%) had ≥ 30% PSA declines by C4 and did not switch taxane, 15 patients (24.6%) who did not achieve ≥ 30% PSA declines by C4 switched taxane, and 13 patients (21.3%) discontinued therapy before or at C4. Of patients switching taxane, 46.7% subsequently achieved ≥ 50% PSA decrease. In 26 CTC-evaluable patients, taxane-induced decrease in %ARNL (cycle 1 day 1 v cycle 1 day 8) was associated with a higher rate of ≥ 50% PSA decrease at C4 ( P = .009). Median composite progression-free survival was 9.1 months (95% CI, 4.9 to 11.7 months); median overall survival was not reached at 14 months. Common grade 3 or 4 adverse events included fatigue (13.1%) and febrile neutropenia (11.5%). Conclusion The early taxane switch strategy was associated with improved PSA response rates versus TAX327. Taxane-induced shifts in %ARNL may serve as an early biomarker of clinical benefit in patients treated with taxanes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Antonarakis ES, Tagawa ST, Galletti G, et al. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. J Clin Oncol. 2017. PMID: 28632486. doi:10.1200/JCO.2017.72.4138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。